ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) as per attached letter on 13th November, 2019. Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder(s) or their legal heir(s) of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s). Alembic Pharma Q2 standalone net up 7 per cent
Pharma player, Alembic Pharmaceuticals Limited registered standalone net profit of Rs 269 crore, for the quarter ended September 2019, as against Rs 2 Alembic Pharmaceuticals Ltd - 533573 - Unaudited Financial Results For The Qaurter And Half Year Ended 30Th September, 2019.
With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results for the quarter and half year ended on 30th September, 2019. The time of commencement of the Board Meeting was 11:30 a.m. and the time of conclusion was 3:15 p.m. Company news: Alembic Pharmaceuticals
Alembic Pharmaceuticals's joint venture Aleor Dermaceuticals has received an approval from the US Food & Drug Administration for its Abbreviated N Alembic Pharmaceuticals Ltd - 533573 - Outcome of Board Meeting
With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results for the quarter and half year ended on 30th September, 2019. The time of commencement of the Board Meeting was 11:30 a.m. and the time of conclusion was 3:15 p.m. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's joint venture, Aleor Dermaceuticals Limited, has received US Food and Drug Administration (USFDA) Approval for Desonide Ointment, 0.05%. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) and / or legal hier(s) of the registered shareholders on 23rd October, 2019 as mentioned in the attached file. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates published by the Company on behalf of the shareholder(s) and / or legal heir(s) of the registered shareholder(s) in English language newspaper - Business Standard on 23rd October, 2019. We request you to kindly take the same on record. Company news | Alembic Pharmaceuticals
Alembic Pharmaceuticals on Tuesday announced that its joint venture Aleor Dermaceuticals Ltd (Aleor) has received approval from the USFDA for its ANDA